Advertisement

Osteoporosis International

, Volume 29, Issue 5, pp 1009–1022 | Cite as

Anabolic agents: what is beyond osteoporosis?

  • Y. Liu
  • A. E. Levack
  • E. Marty
  • O. Or
  • B. P. Samuels
  • M. Redko
  • J. M. Lane
Review

Abstract

Osteoporosis is a common skeletal disorder characterized by low bone mass, which leads to reduced bone strength and an increased risk of fractures. Anabolic agents have been shown to improve bone mass and decrease fracture risk in osteoporosis patients by directly stimulating osteoblasts to produce new bone. Currently, two anabolic agents are available in the USA: recombinantly produced teriparatide (TPTD), which is the fully active (1–34) amino active sequence of human parathyroid hormone (PTH), and abaloparatide (APTD), a synthetic analog of parathyroid hormone-related peptide (PTHrP). At present, both agents are approved only for treatment of patients with osteoporosis at high risk of fracture. Nonetheless, their anabolic properties have led to off-label application in additional settings which include spine fusion, osteonecrosis of the jaw, arthroplasty, and fracture healing. In this article, we summarize available scientific literature regarding the efficacy, effectiveness, and safety of TPTD in these off-label settings.

Keywords

Anabolic agent Fracture Osteoporosis Teriparatide 

Notes

Compliance with ethical standards

Conflict of interest

Dr. Joseph Lane is a co-principal investigator for a trial of teriparatide and pelvic fracture (NIH: 1U01AR069869-01). Ashley E. Levack is supported by NIH T32 AR007281. Yi Liu, Eric Marty, Omer Or, Blossom P. Samuels, and Mariya Redko declare that they have no conflict of interest.

References

  1. 1.
    Ensrud KE, Crandall CJ (2017) Osteoporosis. Ann Intern Med 167:ITC17–ITC32CrossRefPubMedGoogle Scholar
  2. 2.
    Sozen T, Ozisik L, Basaran NC (2017) An overview and management of osteoporosis. Eur J Rheumatol 4:46–56CrossRefPubMedGoogle Scholar
  3. 3.
    Chew CK, Clarke BL (2017) Abaloparatide: recombinant human PTHrP (1-34) anabolic therapy for osteoporosis. Maturitas 97:53–60CrossRefPubMedGoogle Scholar
  4. 4.
    Saag KG, Shane E, Boonen S, Marin F, Donley DW, Taylor KA, Dalsky GP, Marcus R (2007) Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med 357:2028–2039CrossRefPubMedGoogle Scholar
  5. 5.
    Canalis E, Giustina A, Bilezikian JP (2007) Mechanisms of anabolic therapies for osteoporosis. N Engl J Med 357:905–916CrossRefPubMedGoogle Scholar
  6. 6.
    Hattersley G, Dean T, Corbin BA, Bahar H, Gardella TJ (2016) Binding selectivity of abaloparatide for PTH-type-1-receptor conformations and effects on downstream signaling. Endocrinology 157:141–149CrossRefPubMedGoogle Scholar
  7. 7.
    Miller PD, Hattersley G, Riis BJ, Williams GC, Lau E, Russo LA, Alexandersen P, Zerbini CAF, Hu MY, Harris AG, Fitzpatrick LA, Cosman F, Christiansen C, for the ACTIVE Study Investigators (2016) Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial. JAMA 316:722–733CrossRefPubMedGoogle Scholar
  8. 8.
    Langdahl BL, Libanati C, Crittenden DB, Bolognese MA, Brown JP, Daizadeh NS, Dokoupilova E, Engelke K, Finkelstein JS, Genant HK, Goemaere S, Hyldstrup L, Jodar-Gimeno E, Keaveny TM, Kendler D, Lakatos P, Maddox J, Malouf J, Massari FE, Molina JF, Ulla MR, Grauer A (2017) Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial. In: Lancet, vol 390, pp 1585–1594Google Scholar
  9. 9.
    Saag KG, Petersen J, Brandi ML, Karaplis AC, Lorentzon M, Thomas T, Maddox J, Fan M, Meisner PD, Grauer A (2017) Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J MedGoogle Scholar
  10. 10.
    Chaudhary N, Lee JS, Wu JY, Tharin S (2017) Evidence for use of teriparatide in spinal fusion surgery in osteoporotic patients. World Neurosurg 100:551–556CrossRefPubMedGoogle Scholar
  11. 11.
    Yishake M, Yasen M, Jiang L, Liu W, Xing R, Chen Q, Lin H, Dong J (2017) Effects of combined teriparatide and zoledronic acid on posterior lumbar vertebral fusion in an aged ovariectomized rat model of osteopenia. J Orthop ResGoogle Scholar
  12. 12.
    Sugiura T, Kashii M, Matsuo Y, Morimoto T, Honda H, Kaito T, Iwasaki M, Yoshikawa H (2015) Intermittent administration of teriparatide enhances graft bone healing and accelerates spinal fusion in rats with glucocorticoid-induced osteoporosis. Spine J 15:298–306CrossRefPubMedGoogle Scholar
  13. 13.
    Lina IA, Puvanesarajah V, Liauw JA et al (2014) Quantitative study of parathyroid hormone (1-34) and bone morphogenetic protein-2 on spinal fusion outcomes in a rabbit model of lumbar dorsolateral intertransverse process arthrodesis. Spine (Phila Pa 1976) 39:347–355CrossRefGoogle Scholar
  14. 14.
    Qiu Z, Wei L, Liu J, Sochacki KR, Liu X, Bishop C, Ebraheim M, Yang H (2013) Effect of intermittent PTH (1-34) on posterolateral spinal fusion with iliac crest bone graft in an ovariectomized rat model. Osteoporos Int 24:2693–2700CrossRefPubMedGoogle Scholar
  15. 15.
    Ming N, Cheng JT, Rui YF, Chan KM, Kuhstoss S, Ma YL, Sato M, Wang Y, Li G (2012) Dose-dependent enhancement of spinal fusion in rats with teriparatide (PTH[1–34]). Spine (Phila Pa 1976) 37:1275–1282CrossRefGoogle Scholar
  16. 16.
    Lehman RA Jr, Dmitriev AE, Cardoso MJ, Helgeson MD, Christensen CL, Raymond JW, Eckel TT, Riew KD (2010) Effect of teriparatide [rhPTH(1,34)] and calcitonin on intertransverse process fusion in a rabbit model. Spine (Phila Pa 1976) 35:146–152CrossRefGoogle Scholar
  17. 17.
    O'Loughlin PF, Cunningham ME, Bukata SV, Tomin E, Poynton AR, Doty SB, Sama AA, Lane JM (2009) Parathyroid hormone (1-34) augments spinal fusion, fusion mass volume, and fusion mass quality in a rabbit spinal fusion model. Spine (Phila Pa 1976) 34:121–130CrossRefGoogle Scholar
  18. 18.
    Abe Y, Takahata M, Ito M, Irie K, Abumi K, Minami A (2007) Enhancement of graft bone healing by intermittent administration of human parathyroid hormone (1-34) in a rat spinal arthrodesis model. Bone 41:775–785CrossRefPubMedGoogle Scholar
  19. 19.
    Lawrence JP, Ennis F, White AP, Magit D, Polzhofer G, Drespe I, Troiano NW, Grauer JN (2006) Effect of daily parathyroid hormone (1-34) on lumbar fusion in a rat model. Spine J 6:385–390CrossRefPubMedGoogle Scholar
  20. 20.
    Keskinruzgar A, Bozdag Z, Aras MH, Demir T, Yolcu U, Cetiner S (2016) Histopathological effects of teriparatide in medication-related osteonecrosis of the jaw: an animal study. J Oral Maxillofac Surg 74:68–78CrossRefPubMedGoogle Scholar
  21. 21.
    Dayisoylu EH, Senel FC, Ungor C, Tosun E, Cankaya M, Ersoz S, Taskesen F (2013) The effects of adjunctive parathyroid hormone injection on bisphosphonate-related osteonecrosis of the jaws: an animal study. Int J Oral Maxillofac Surg 42:1475–1480CrossRefPubMedGoogle Scholar
  22. 22.
    Daugaard H, Elmengaard B, Andreassen T, Bechtold J, Lamberg A, Soballe K (2011) Parathyroid hormone treatment increases fixation of orthopedic implants with gap healing: a biomechanical and histomorphometric canine study of porous coated titanium alloy implants in cancellous bone. Calcif Tissue Int 88:294–303CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Li YF, Li XD, Bao CY, Chen QM, Zhang H, Hu J (2013) Promotion of peri-implant bone healing by systemically administered parathyroid hormone (1-34) and zoledronic acid adsorbed onto the implant surface. Osteoporos Int 24:1063–1071CrossRefPubMedGoogle Scholar
  24. 24.
    Nakajima A, Shimoji N, Shiomi K, Shimizu S, Moriya H, Einhorn TA, Yamazaki M (2002) Mechanisms for the enhancement of fracture healing in rats treated with intermittent low-dose human parathyroid hormone (1-34). J Bone Miner Res 17:2038–2047CrossRefPubMedGoogle Scholar
  25. 25.
    Andreassen TT, Ejersted C, Oxlund H (1999) Intermittent parathyroid hormone (1-34) treatment increases callus formation and mechanical strength of healing rat fractures. J Bone Miner Res 14:960–968CrossRefPubMedGoogle Scholar
  26. 26.
    Alkhiary YM, Gerstenfeld LC, Krall E, Westmore M, Sato M, Mitlak BH, Einhorn TA (2005) Enhancement of experimental fracture-healing by systemic administration of recombinant human parathyroid hormone (PTH 1-34). J Bone Joint Surg Am 87:731–741PubMedGoogle Scholar
  27. 27.
    Manabe T, Mori S, Mashiba T, Kaji Y, Iwata K, Komatsubara S, Seki A, Sun YX, Yamamoto T (2007) Human parathyroid hormone (1-34) accelerates natural fracture healing process in the femoral osteotomy model of cynomolgus monkeys. Bone 40:1475–1482CrossRefPubMedGoogle Scholar
  28. 28.
    Tagil M, McDonald MM, Morse A, Peacock L, Mikulec K, Amanat N, Godfrey C, Little DG (2010) Intermittent PTH(1-34) does not increase union rates in open rat femoral fractures and exhibits attenuated anabolic effects compared to closed fractures. Bone 46:852–859CrossRefPubMedGoogle Scholar
  29. 29.
    Morgan EF, Mason ZD, Bishop G, Davis AD, Wigner NA, Gerstenfeld LC, Einhorn TA (2008) Combined effects of recombinant human BMP-7 (rhBMP-7) and parathyroid hormone (1-34) in metaphyseal bone healing. Bone 43:1031–1038CrossRefPubMedGoogle Scholar
  30. 30.
    Cohn Yakubovich D, Sheyn D, Bez M, Schary Y, Yalon E, Sirhan A, Amira M, Yaya A, de Mel S, da X, Ben-David S, Tawackoli W, Ley EJ, Gazit D, Gazit Z, Pelled G (2017) Systemic administration of mesenchymal stem cells combined with parathyroid hormone therapy synergistically regenerates multiple rib fractures. Stem Cell Res Ther 8:51CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Li YF, Zhou CC, Li JH, Luo E, Zhu SS, Feng G, Hu J (2012) The effects of combined human parathyroid hormone (1-34) and zoledronic acid treatment on fracture healing in osteoporotic rats. Osteoporos Int 23:1463–1474CrossRefPubMedGoogle Scholar
  32. 32.
    Komrakova M, Stuermer EK, Werner C, Wicke M, Kolios L, Sehmisch S, Tezval M, Daub F, Martens T, Witzenhausen P, Dullin C, Stuermer KM (2010) Effect of human parathyroid hormone hPTH (1-34) applied at different regimes on fracture healing and muscle in ovariectomized and healthy rats. Bone 47:480–492CrossRefPubMedGoogle Scholar
  33. 33.
    Lin EA, Liu CJ, Monroy A, Khurana S, Egol KA (2012) Prevention of atrophic nonunion by the systemic administration of parathyroid hormone (PTH 1-34) in an experimental animal model. J Orthop Trauma 26:719–723CrossRefPubMedGoogle Scholar
  34. 34.
    Sloan AV, Martin JR, Li S, Li J (2010) Parathyroid hormone and bisphosphonate have opposite effects on stress fracture repair. Bone 47:235–240CrossRefPubMedGoogle Scholar
  35. 35.
    Ohtori S, Orita S, Yamauchi K, Eguchi Y, Aoki Y, Nakamura J, Suzuki M, Kubota G, Inage K, Shiga Y, Abe K, Fujimoto K, Kanamoto H, Inoue M, Kinoshita H, Furuya T, Koda M (2017) Does discontinuing teriparatide treatment and replacing it with bisphosphonate maintain the volume of the bone fusion mass after lumbar posterolateral fusion in women with postmenopausal osteoporosis? Asian Spine J 11:272–277CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Kaliya-Perumal AK, Lu ML, Luo CA, Tsai TT, Lai PL, Chen LH, Chen WJ, Niu CC (2017) Retrospective radiological outcome analysis following teriparatide use in elderly patients undergoing multilevel instrumented lumbar fusion surgery. Medicine (Baltimore) 96:e5996CrossRefGoogle Scholar
  37. 37.
    Ohtori S, Orita S, Yamauchi K, Eguchi Y, Ochiai N, Kuniyoshi K, Aoki Y, Nakamura J, Miyagi M, Suzuki M, Kubota G, Inage K, Sainoh T, Sato J, Shiga Y, Abe K, Fujimoto K, Kanamoto H, Inoue G, Takahashi K (2015) More than 6 months of teriparatide treatment was more effective for bone union than shorter treatment following lumbar posterolateral fusion surgery. Asian Spine J 9:573–580CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Inoue G, Ueno M, Nakazawa T, Imura T, Saito W, Uchida K, Ohtori S, Toyone T, Takahira N, Takaso M (2014) Teriparatide increases the insertional torque of pedicle screws during fusion surgery in patients with postmenopausal osteoporosis. J Neurosurg Spine 21:425–431CrossRefPubMedGoogle Scholar
  39. 39.
    Cho PG, Ji GY, Shin DA, Ha Y, Yoon DH, Kim KN (2017) An effect comparison of teriparatide and bisphosphonate on posterior lumbar interbody fusion in patients with osteoporosis: a prospective cohort study and preliminary data. Eur Spine J 26:691–697CrossRefPubMedGoogle Scholar
  40. 40.
    Ebata S, Takahashi J, Hasegawa T, Mukaiyama K, Isogai Y, Ohba T, Shibata Y, Ojima T, Yamagata Z, Matsuyama Y, Haro H (2017) Role of weekly teriparatide administration in osseous union enhancement within six months after posterior or transforaminal lumbar interbody fusion for osteoporosis-associated lumbar degenerative disorders: a multicenter, prospective randomized study. J Bone Joint Surg Am 99:365–372CrossRefPubMedGoogle Scholar
  41. 41.
    Seki S, Hirano N, Kawaguchi Y, Nakano M, Yasuda T, Suzuki K, Watanabe K, Makino H, Kanamori M, Kimura T (2017) Teriparatide versus low-dose bisphosphonates before and after surgery for adult spinal deformity in female Japanese patients with osteoporosis. Eur Spine J 26:2121–2127CrossRefPubMedGoogle Scholar
  42. 42.
    Ohtori S, Inoue G, Orita S, Yamauchi K, Eguchi Y, Ochiai N, Kishida S, Kuniyoshi K, Aoki Y, Nakamura J, Ishikawa T, Miyagi M, Kamoda H, Suzuki M, Kubota G, Sakuma Y, Oikawa Y, Inage K, Sainoh T, Takaso M, Toyone T, Takahashi K (2013) Comparison of teriparatide and bisphosphonate treatment to reduce pedicle screw loosening after lumbar spinal fusion surgery in postmenopausal women with osteoporosis from a bone quality perspective. Spine (Phila Pa 1976) 38:E487–E492CrossRefGoogle Scholar
  43. 43.
    Ohtori S, Inoue G, Orita S, Yamauchi K, Eguchi Y, Ochiai N, Kishida S, Kuniyoshi K, Aoki Y, Nakamura J, Ishikawa T, Miyagi M, Kamoda H, Suzuki M, Kubota G, Sakuma Y, Oikawa Y, Inage K, Sainoh T, Takaso M, Ozawa T, Takahashi K, Toyone T (2012) Teriparatide accelerates lumbar posterolateral fusion in women with postmenopausal osteoporosis: prospective study. Spine (Phila Pa 1976) 37:E1464–E1468CrossRefGoogle Scholar
  44. 44.
    Jung J, Yoo HY, Kim GT, Lee JW, Lee YA, Kim DY, Kwon YD (2017) Short-term teriparatide and recombinant human bone morphogenetic protein-2 for regenerative approach to medication-related osteonecrosis of the jaw: a preliminary study. J Bone Miner ResGoogle Scholar
  45. 45.
    Kim KM, Park W, Oh SY, Kim HJ, Nam W, Lim SK, Rhee Y, Cha IH (2014) Distinctive role of 6-month teriparatide treatment on intractable bisphosphonate-related osteonecrosis of the jaw. Osteoporos Int 25:1625–1632CrossRefPubMedGoogle Scholar
  46. 46.
    Kaneko T, Otani T, Kono N, Mochizuki Y, Mori T, Nango N, Ikegami H, Musha Y (2016) Weekly injection of teriparatide for bone ingrowth after cementless total knee arthroplasty. J Orthop Surg (Hong Kong) 24:16–21CrossRefGoogle Scholar
  47. 47.
    Huang TW, Huang KC, Lin SJ, Chuang PY, Shih HN, Lee MS, Hsu RW, Shen WJ (2016) Effects of teriparatide on cementless bipolar hemiarthroplasty in patients with osteoporotic femoral neck fractures. BMC Musculoskelet Disord 17:300CrossRefPubMedPubMedCentralGoogle Scholar
  48. 48.
    Kobayashi N, Inaba Y, Uchiyama M, Ike H, Kubota S, Saito T (2016) Teriparatide versus alendronate for the preservation of bone mineral density after Total hip arthroplasty—a randomized controlled trial. J Arthroplast 31:333–338CrossRefGoogle Scholar
  49. 49.
    Ledin H, Good L, Johansson T, Aspenberg P (2017) No effect of teriparatide on migration in total knee replacement. Acta Orthop 88:259–262CrossRefPubMedPubMedCentralGoogle Scholar
  50. 50.
    Aspenberg P, Genant HK, Johansson T, Nino AJ, See K, Krohn K, García-Hernández PA, Recknor CP, Einhorn TA, Dalsky GP, Mitlak BH, Fierlinger A, Lakshmanan MC (2010) Teriparatide for acceleration of fracture repair in humans: a prospective, randomized, double-blind study of 102 postmenopausal women with distal radial fractures. J Bone Miner Res 25:404–414CrossRefPubMedGoogle Scholar
  51. 51.
    Aspenberg P, Johansson T (2010) Teriparatide improves early callus formation in distal radial fractures. Acta Orthop 81:234–236CrossRefPubMedPubMedCentralGoogle Scholar
  52. 52.
    Peichl P, Holzer LA, Maier R, Holzer G (2011) Parathyroid hormone 1-84 accelerates fracture-healing in pubic bones of elderly osteoporotic women. J Bone Joint Surg Am 93:1583–1587CrossRefPubMedGoogle Scholar
  53. 53.
    Miller PD, McCarthy EF (2015) Bisphosphonate-associated atypical sub-trochanteric femur fractures: paired bone biopsy quantitative histomorphometry before and after teriparatide administration. Semin Arthritis Rheum 44:477–482CrossRefPubMedGoogle Scholar
  54. 54.
    Kim JT, Jeong HJ, Lee SJ, Kim HJ, Yoo JJ (2016) Adjuvant teriparatide therapy for surgical treatment of femoral fractures; does it work? Hip Pelvis 28:148–156CrossRefPubMedPubMedCentralGoogle Scholar
  55. 55.
    Miyakoshi N, Aizawa T, Sasaki S, Ando S, Maekawa S, Aonuma H, Tsuchie H, Sasaki H, Kasukawa Y, Shimada Y (2015) Healing of bisphosphonate-associated atypical femoral fractures in patients with osteoporosis: a comparison between treatment with and without teriparatide. J Bone Miner Metab 33:553–559CrossRefPubMedGoogle Scholar
  56. 56.
    Watts NB, Aggers D, McCarthy EF, Savage T, Martinez S, Patterson R, Carrithers E, Miller PD (2017) Responses to treatment with teriparatide in patients with atypical femur fractures previously treated with bisphosphonates. J Bone Miner Res 32:1027–1033CrossRefPubMedGoogle Scholar
  57. 57.
    Chiang CY, Zebaze RM, Ghasem-Zadeh A, Iuliano-Burns S, Hardidge A, Seeman E (2013) Teriparatide improves bone quality and healing of atypical femoral fractures associated with bisphosphonate therapy. Bone 52:360–365CrossRefPubMedGoogle Scholar
  58. 58.
    Lee YK, Ha YC, Koo KH (2012) Teriparatide, a nonsurgical solution for femoral nonunion? A report of three cases. Osteoporos Int 23:2897–2900CrossRefPubMedGoogle Scholar
  59. 59.
    Xiaofeng L, Daxia X, Yunzhen C (2017) Teriparatide as a nonoperative treatment for tibial and femoral fracture nonunion: a case report. Medicine (Baltimore) 96:e6571CrossRefGoogle Scholar
  60. 60.
    Emanuele C, Leonardo P, Gianfilippo C, Matteo A, Doria C (2017) Peri-prosthetic humeral non-union: where biology meets bio-mechanic. A case report. Int J Surg Case Rep 39:102–105CrossRefPubMedPubMedCentralGoogle Scholar
  61. 61.
    Bednar DA (2013) Teriparatide treatment of a glucocorticoid-associated resorbing nonunion of a type III odontoid process fracture: a case report. J Spinal Disord Tech 26:E319–E322CrossRefPubMedGoogle Scholar
  62. 62.
    Raghavan P, Christofides E (2012) Role of teriparatide in accelerating metatarsal stress fracture healing: a case series and review of literature. Clin Med Insights Endocrinol Diabetes 5:39–45CrossRefPubMedPubMedCentralGoogle Scholar
  63. 63.
    Whyte MP, Mumm S, Deal C (2007) Adult hypophosphatasia treated with teriparatide. J Clin Endocrinol Metab 92:1203–1208CrossRefPubMedGoogle Scholar
  64. 64.
    Zanchetta JR, Bogado CE, Ferretti JL, Wang O, Wilson MG, Sato M, Gaich GA, Dalsky GP, Myers SL (2003) Effects of teriparatide [recombinant human parathyroid hormone (1-34)] on cortical bone in postmenopausal women with osteoporosis. J Bone Miner Res 18:539–543CrossRefPubMedGoogle Scholar
  65. 65.
    Schnell R, Graeff C, Krebs A, Oertel H, Gluer CC (2010) Changes in cross-sectional area of spinal canal and vertebral body under 2 years of teriparatide treatment: results from the EUROFORS study. Calcif Tissue Int 87:130–136CrossRefPubMedPubMedCentralGoogle Scholar
  66. 66.
    Cheung A, Seeman E (2010) Teriparatide therapy for alendronate-associated osteonecrosis of the jaw. N Engl J Med 363:2473–2474CrossRefPubMedGoogle Scholar
  67. 67.
    El-Rabbany M, Sgro A, Lam DK, Shah PS, Azarpazhooh A (2017) Effectiveness of treatments for medication-related osteonecrosis of the jaw: a systematic review and meta-analysis. J Am Dent Assoc 148(584–594):e582Google Scholar
  68. 68.
    Yoshiga D, Yamashita Y, Nakamichi I, Tanaka T, Yamauchi K, Yamamoto N, Nogami S, Kaneuji T, Mitsugi S, Sakurai T, Kiyomiya H, Tominaga K, Morimoto Y, Takahashi T (2013) Weekly teriparatide injections successfully treated advanced bisphosphonate-related osteonecrosis of the jaws. Osteoporos Int 24:2365–2369CrossRefPubMedPubMedCentralGoogle Scholar
  69. 69.
    Bashutski JD, Eber RM, Kinney JS, Benavides E, Maitra S, Braun TM, Giannobile WV, McCauley LK (2010) Teriparatide and osseous regeneration in the oral cavity. N Engl J Med 363:2396–2405CrossRefPubMedPubMedCentralGoogle Scholar
  70. 70.
    Khan AA, Morrison A, Hanley DA, Felsenberg D, McCauley LK, O'Ryan F, Reid IR, Ruggiero SL, Taguchi A, Tetradis S, Watts NB, Brandi ML, Peters E, Guise T, Eastell R, Cheung AM, Morin SN, Masri B, Cooper C, Morgan SL, Obermayer-Pietsch B, Langdahl BL, al Dabagh R, Davison KS, Kendler DL, Sándor GK, Josse RG, Bhandari M, el Rabbany M, Pierroz DD, Sulimani R, Saunders DP, Brown JP, Compston J, on behalf of the International Task Force on Osteonecrosis of the Jaw (2015) Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res 30:3–23CrossRefPubMedGoogle Scholar
  71. 71.
    Subbiah V, Madsen VS, Raymond AK, Benjamin RS, Ludwig JA (2010) Of mice and men: divergent risks of teriparatide-induced osteosarcoma. Osteoporos Int 21:1041–1045CrossRefPubMedGoogle Scholar
  72. 72.
    Oteo-Alvaro A, Matas JA, Alonso-Farto JC (2011) Teriparatide (rh [1-34] PTH) improved osteointegration of a hemiarthroplasty with signs of aseptic loosening. Orthopedics 34:e574–e577PubMedGoogle Scholar
  73. 73.
    Zati A, Sarti D, Malaguti MC, Pratelli L (2011) Teriparatide in the treatment of a loose hip prosthesis. J Rheumatol 38:778–780CrossRefPubMedGoogle Scholar
  74. 74.
    Suzuki T, Ryu K, Kojima K, Saito S, Nagaoka H, Tokuhashi Y (2017) Teriparatide treatment improved loosening of cementless total knee arthroplasty: a case report. J Orthop Case Rep 7:32–35PubMedPubMedCentralGoogle Scholar
  75. 75.
    Einhorn TA, Gerstenfeld LC (2015) Fracture healing: mechanisms and interventions. Nat Rev Rheumatol 11:45–54CrossRefPubMedGoogle Scholar
  76. 76.
    Kakar S, Einhorn TA, Vora S, Miara LJ, Hon G, Wigner NA, Toben D, Jacobsen KA, al-Sebaei MO, Song M, Trackman PC, Morgan EF, Gerstenfeld LC, Barnes GL (2007) Enhanced chondrogenesis and Wnt signaling in PTH-treated fractures. J Bone Miner Res 22:1903–1912CrossRefPubMedGoogle Scholar
  77. 77.
    Shane E, Burr D, Abrahamsen B, Adler RA, Brown TD, Cheung AM, Cosman F, Curtis JR, Dell R, Dempster DW, Ebeling PR, Einhorn TA, Genant HK, Geusens P, Klaushofer K, Lane JM, McKiernan F, McKinney R, Ng A, Nieves J, O'Keefe R, Papapoulos S, Howe TS, van der Meulen MCH, Weinstein RS, Whyte MP (2014) Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 29:1–23CrossRefPubMedGoogle Scholar
  78. 78.
    Gomberg SJ, Wustrack RL, Napoli N, Arnaud CD, Black DM (2011) Teriparatide, vitamin D, and calcium healed bilateral subtrochanteric stress fractures in a postmenopausal woman with a 13-year history of continuous alendronate therapy. J Clin Endocrinol Metab 96:1627–1632CrossRefPubMedGoogle Scholar
  79. 79.
    Carvalho NN, Voss LA, Almeida MO, Salgado CL, Bandeira F (2011) Atypical femoral fractures during prolonged use of bisphosphonates: short-term responses to strontium ranelate and teriparatide. J Clin Endocrinol Metab 96:2675–2680CrossRefPubMedGoogle Scholar
  80. 80.
    Tjhia CK, Odvina CV, Rao DS, Stover SM, Wang X, Fyhrie DP (2011) Mechanical property and tissue mineral density differences among severely suppressed bone turnover (SSBT) patients, osteoporotic patients, and normal subjects. Bone 49:1279–1289CrossRefPubMedPubMedCentralGoogle Scholar
  81. 81.
    Seeman E, Delmas PD (2006) Bone quality—the material and structural basis of bone strength and fragility. N Engl J Med 354:2250–2261CrossRefPubMedGoogle Scholar
  82. 82.
    Moreira CA, Bilezikian JP (2017) Stress fractures: concepts and therapeutics. J Clin Endocrinol Metab 102:525–534PubMedGoogle Scholar

Copyright information

© International Osteoporosis Foundation and National Osteoporosis Foundation 2018

Authors and Affiliations

  • Y. Liu
    • 1
  • A. E. Levack
    • 1
  • E. Marty
    • 1
  • O. Or
    • 1
    • 2
  • B. P. Samuels
    • 1
  • M. Redko
    • 1
  • J. M. Lane
    • 1
  1. 1.Department of Orthopedic Surgery, Hospital for Special SurgeryWeill Cornell Medical CollegeNew YorkUSA
  2. 2.Department of Orthopedic SurgeryHadassah Medical CenterJerusalemIsrael

Personalised recommendations